以岭药业
(002603)
| 流通市值：194.69亿 | | | 总市值：236.24亿 |
| 流通股本：13.77亿 | | | 总股本：16.71亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,358,232,707.77 | 6,512,734,471.77 | 6,365,441,001.17 | 4,604,485,816.89 |
| 营业收入 | 2,358,232,707.77 | 6,512,734,471.77 | 6,365,441,001.17 | 4,604,485,816.89 |
| 二、营业总成本 | 1,946,902,188.1 | 7,147,123,381.22 | 5,723,859,252.05 | 3,978,871,341.64 |
| 营业成本 | 1,088,979,435.66 | 3,244,208,648.07 | 2,966,689,927.87 | 2,147,158,224.84 |
| 税金及附加 | 30,250,648.89 | 119,211,877.27 | 92,543,140.09 | 71,956,228.65 |
| 销售费用 | 547,039,894.43 | 2,334,704,305.07 | 1,672,009,793.12 | 1,077,919,466.42 |
| 管理费用 | 117,453,827.72 | 600,011,013.3 | 395,046,421.77 | 271,382,273.04 |
| 研发费用 | 164,030,341.5 | 826,572,646.79 | 571,912,835.78 | 393,289,796.04 |
| 财务费用 | -851,960.1 | 22,414,890.72 | 25,657,133.42 | 17,165,352.65 |
| 其中:利息费用 | 139,827.92 | 29,006,743.88 | 28,465,206.58 | 20,040,003.71 |
| 其中:利息收入 | 1,467,295.44 | 8,001,089.51 | 5,607,750.08 | 4,070,555.44 |
| 加:公允价值变动收益 | - | - | 38,863,277.79 | 25,905,930.58 |
| 加:投资收益 | -495,638.12 | 39,808,208.41 | 501,146.91 | 927,290.25 |
| 资产处置收益 | -87.07 | -487,181.84 | -1,763,045.54 | -982,250.89 |
| 资产减值损失(新) | -20,228,830.71 | -248,337,301.39 | -4,677,546.02 | -3,118,364.01 |
| 信用减值损失(新) | 2,150,899.78 | -10,297,019.75 | -17,641,197.58 | -6,707,184.39 |
| 其他收益 | 5,815,450.27 | 164,806,751.97 | 46,269,378.55 | 29,318,935.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 398,572,313.82 | -688,895,452.05 | 703,133,763.23 | 670,958,832.67 |
| 加:营业外收入 | 6,268,964.61 | 10,472,588.05 | 2,499,457.21 | 1,198,980.25 |
| 减:营业外支出 | 10,720,228.07 | 121,769,143.83 | 33,524,829.83 | 28,835,737.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 394,121,050.36 | -800,192,007.83 | 672,108,390.61 | 643,322,075.42 |
| 减:所得税费用 | 69,965,135.6 | -66,008,475.57 | 123,021,537.87 | 116,695,700.53 |
| 六、净利润 | 324,155,914.76 | -734,183,532.26 | 549,086,852.74 | 526,626,374.89 |
| 持续经营净利润 | 324,155,914.76 | -734,183,532.26 | 549,086,852.74 | 526,626,374.89 |
| 归属于母公司股东的净利润 | 325,953,296.25 | -724,515,582.24 | 554,776,843.41 | 530,457,109.15 |
| 少数股东损益 | -1,797,381.49 | -9,667,950.02 | -5,689,990.67 | -3,830,734.26 |
| (一)基本每股收益 | 0.2 | -0.43 | 0.33 | 0.32 |
| (二)稀释每股收益 | 0.2 | -0.43 | 0.33 | 0.32 |
| 八、其他综合收益 | -54,894.21 | -507,389.2 | 551,883.75 | 20,576.61 |
| 归属于母公司股东的其他综合收益 | -54,894.21 | -507,389.2 | 551,883.75 | 20,576.61 |
| 九、综合收益总额 | 324,101,020.55 | -734,690,921.46 | 549,638,736.49 | 526,646,951.5 |
| 归属于母公司股东的综合收益总额 | 325,898,402.04 | -725,022,971.44 | 555,328,727.16 | 530,477,685.76 |
| 归属于少数股东的综合收益总额 | -1,797,381.49 | -9,667,950.02 | -5,689,990.67 | -3,830,734.26 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |